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Abstract: Primary ciliary dyskinesia (PCD) is a heterogeneous autosomal recessive 
condition affecting around 1:15,000. In people with PCD, microscopic motile cilia do not 
move normally resulting in impaired clearance of mucus and debris leading to repeated 
sinopulmonary infection. If diagnosis is delayed, permanent bronchiectasis and deterioration of 
lung function occurs. Other complications associated with PCD include congenital heart 
disease, hearing impairment and infertility. A small number of longitudinal studies suggest 
that lung function deteriorates before diagnosis of PCD but may stabilise following 
diagnosis with subsequent specialist management. Early diagnosis is therefore essential, 
but for a number of reasons referral for diagnostic testing is often delayed until older 
childhood or even adulthood. Functional diagnostic tests for PCD are expensive, time 
consuming and require specialist equipment and scientists. In the last few years, there have 
been considerable developments to identify genes associated with PCD, currently enabling 
65% of patients to be identified by bi-allelic mutations. The rapid identification of new 
genes continues. This review will consider the evidence that early diagnosis of PCD is 
beneficial. It will review the recent advances in identification of PCD-associated genes and 
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will discuss the role of genetic testing in PCD. It will then consider whether screening for 
PCD antenatally or in the new born is likely to become a feasible and acceptable for  
this rare disease. 
Keywords: primary ciliary dyskinesia; cystic fibrosis; genetic testing; screening; mutation; 
cilia; diagnosis 
 
1. Introduction 
Primary ciliary dyskinesia (PCD) is an inherited disorder of the function of motile cilia and  
sperm flagella, usually associated with abnormalities of the cilial ultrastructure as observed by  
electron microscopy (EM). It has an incidence of around 1 in 15,000 live births [1,2], however it is 
considerably more prevalent in certain populations, for example a consanguineous British Asian 
population has a prevalence of 1:2265 [3]. The majority of patients are symptomatic from birth and go 
on to have persistent or recurrent sinopulmonary infection. Around half of patients have associated 
situs inversus (Kartagener’s syndrome) or other disorders of left-right asymmetry [4]. Diagnosis is 
often delayed with only half of cases identified before 5 years of age [2]. Evidence that later diagnosis 
is associated with poorer lung function and quality of life [5,6] highlights the need for early diagnosis. 
Cystic fibrosis (CF) shares a number of features with PCD including progressive bronchiectatic disease 
and decline in lung function. The advent of neonatal screening for CF has allowed earlier diagnosis 
with potential improvements in long-term lung function and morbidity [7]. 
Siewert first described the triad of situs inversus, bronchiectasis and sinusitis in 1904, with the term 
Kartagener’s syndrome coined following his 1935 description. In 1976, Afzelius was the first to link 
this disease to cilia and termed the disease “immotile cilia syndrome” [8]. DNAH5 was identified as a 
candidate gene for PCD in 2000 [9] and shortly after was characterized and confirmed to be associated 
with PCD and randomization of left-right symmetry [10]. Rapid advances in understanding the 
molecular genetic basis of PCD have been made in recent years. 
Motile cilia are found in respiratory epithelium, brain ependymal cells, spinal cord and fallopian 
tubes whilst sharing a common axonemal structure with spermatozoa flagella. Cilial axonemes of 
healthy individuals have a “9 + 2” arrangement with nine pairs of microtubule doublets surrounding a 
central pair running the length of the ciliary axoneme (Figures 1 and 2). Attached to the peripheral 
microtubules are inner and outer dynein arms in which dynein, a mechanochemical ATPase, generates 
the force for ciliary beating. The organized structure is maintained by nexin and radial spokes. Defects 
in the ultrastructure cause the cilia to beat abnormally, impairing mucociliary clearance leading to 
sinopulmonary disease, glue ear and female sub-fertility. Abnormalities of the ultrastructure of sperm 
flagella can lead to dysmotility and infertility. PCD in humans rarely causes hydrocephalus. The  
“9 + 0” motile cilia (no central pair) are present on the embryonic ventral node and have a role in 
determining left-right symmetry. Abnormal ciliary function in these embryonal cilia can lead to the 
classic situs inversus described by Kartagener where the organs are a mirror image or other disorders 
of situs termed heterotaxy (including left isomerism, right isomerism, isolated dextrocardia and 
abdominal situs inversus) [4,11]. 
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Figure 1. Diagram showing the main structural elements of the human motile cilium with 
the “9 + 2” arrangement. 
 
Figure 2. Scanning electron microscope image of a human cilium with normal ultrastructure. 
 
Consistent with the many proteins involved in ciliary structure, protein assembly and intraflagellar 
transport PCD is a markedly heterogeneous disorder. To date, almost 30 genes have been found to be 
associated with PCD [12], mostly linked to specific ultrastructural defects, but it is anticipated that 
several hundred genes may code for proteins responsible for normal ciliary function. 
Expanding knowledge of PCD genetics has raised the possibility of genetic screening for the 
condition, similarly to neonatal CF screening programs. Approximately 50%–60% of PCD patients 
have bi-allelic mutations in genes that are currently known to be associated with PCD making testing 
to support diagnosis a reality [12]. Current hurdles include the large number of PCD genes that are as 
yet unidentified, lack of a good supporting screening test for neonates, and the relatively low incidence 
of the disease in most populations. This manuscript reviews the need for, and possibility of, early 
screening for PCD in high-risk populations. 
J. Clin. Med. 2014, 3 494 
 
 
2. Diagnosis of PCD 
Diagnostic investigations for PCD are highly specialised, requiring expensive equipment and an 
experienced team of clinicians and scientists [13]. European consensus guidelines [14] reflect the  
need for access to a number of methods to ensure robust diagnosis, as there is no single “gold  
standard” investigation. 
Ciliary defects in PCD were first identified using electron microscopy [8] and this remained the 
“gold standard” diagnostic tool for many years. Samples of ciliated respiratory epithelium can be 
collected from nasal or bronchial brushing biopsy and approximately 100 cilia examined in transverse 
section to identify abnormalities of the outer or inner dynein arms, central pairs or microtubular 
arrangement [15]. A 3%–30% of patients with PCD are reported to have normal ultrastructure [16,17] 
and assessment of ciliary function is therefore necessary to exclude PCD. Ciliated respiratory cells 
obtained by brush biopsy can be imaged by high resolution, high-speed video (HSV) microscopy [18]. 
The images are played back at slower speed to allow analysis of beat pattern. Ciliary beat frequency is 
normally 11–18 Hz (measured at 37 °C) but in patients with PCD the beat frequency is typically  
static, slow or hyperfrequent. Less often the beat frequency is normal but the sweep or beat pattern 
abnormal [15]. These dysmotile patterns are often associated with specific transmission electron 
microscope (TEM) defects [19], for example in outer dynein arm (ODA) or combined inner dynein 
arm (IDA) and ODA defects, the majority of cilia are static, whilst with central pair defects cilia make 
a rotating motion rather than sweeping. Recently, subtle abnormalities of beat pattern [20] have been 
shown to be associated with the full PCD phenotype demonstrating the need for analysis of ciliary beat 
pattern by experienced technicians. HSV analysis is frequently complicated by secondary ciliary 
dyskinesia, which is common in patients with viral infections or simply due to damage to the 
epithelium during sampling [21]. 
In recent years, additional diagnostic tests have been added to support the diagnostic portfolio, 
particularly where HSV analysis and electron microscope (EM) examination are inconclusive. Cell 
culture of biopsy samples prior to re-analysis by HSV and EM minimises secondary ciliary  
defects [22] and immunofluorescent analysis of proteins can define ciliary defects [23]. Radioaerosol 
mucociliary clearance provides an in vivo assessment of ciliary function [24]. However, these 
additional investigations are only available at a handful of centres, often as a research rather than 
clinical tool. Genetic testing is not yet routine in most countries but the recent rapid increase in 
identified mutations that is reviewed below makes it likely that PCD genetics testing will soon become 
part of the diagnostic pathway. 
Nasal nitric oxide (nNO) is extremely low in most, but not all, patients with PCD and therefore 
provides a good screening test [25–28]. Nasal NO can be measured using commercially available 
analysers, which sample gas from the upper airway (transnasal flow) during breath-holding or tidal 
breathing [29]. Infants with PCD have low nNO [30,31], and measurement during tidal breathing is 
possible in most young children [32]. The main drawback of nNO as a screening test in infants is poor 
specificity since approximately 40% of healthy young children have low levels [33]. There is therefore 
no reliable screening test in the group who would benefit most from screening. 
In summary, ciliary EM and HSV are technically challenging, labour intensive processes that 
should be undertaken only in specialist referral centres. Expanded genetic testing might help in 
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identifying patients that need functional assessment and improving the diagnostic process, thus 
impacting on the need to diagnose patients at an early age. 
3. The Need for Early Diagnostics 
The majority of PCD patients have neonatal symptoms and around half have situs inversus but, 
despite these signs, diagnosis is often delayed. This prevents early onset of regular airway clearance 
therapy, aggressive management of infections, monitoring and treatment of hearing impairment and 
genetic counselling for the family. In a series of 55 cases, Coren et al. found the median age at 
diagnosis to be 4 years, even though 67% had neonatal respiratory distress and 69% had abnormal  
situs [5] (with a prevalence of 50% in PCD, this suggests under-recognition in those with normal 
situs). Although 45% of patients had both neonatal symptoms and situs inversus, only half of these 
children were diagnosed before the age of 1 year [5]. Recent survey data from across Europe [2] 
showed the average age at diagnosis to be 5.8 years in those without situs inversus and 3.5 years in 
those with it. It was also noted that diagnosis was earlier in centres caring for more than 20 PCD patients 
(3 years vs. 4 years) emphasizing the importance of clinical suspicion and access to diagnostic tests [2].  
By comparison, the average age of diagnosis for CF is 1.3 years even though it is unusual for these 
patients to have any neonatal symptoms unless they present with meconium ileus [5]. This emphasises 
the importance of clinical suspicion and identification of those at risk as any advances in genetic 
testing will only be useful once applied to the appropriate group of patients. 
Early diagnosis of PCD has the potential to improve patient outcomes; 12 of the patients in the 
Coren series already had bronchiectasis at diagnosis [5]. Age at diagnosis has been shown to affect 
long-term lung function [6] whilst an observational study from North America [34] highlighted that 
PCD can lead to severe respiratory disease in adulthood with a high percentage developing respiratory 
failure and requiring lung transplant. Ellerman and Bisgaard showed that, unlike CF, lung function was 
relatively stable once therapy with antibiotics and airway clearance was initiated [6]. It is anticipated 
that whilst early diagnosis will delay disease progression and improve morbidity, knowledge of the 
diagnosis can also direct appropriate therapy choice; for example, treatment of hearing impairment and 
rhinosinusitis should be treated by specialists with an understanding of PCD as treatment options may 
be different to the general population. 
PCD is therefore a disease that presents with early symptoms and can progress to significant, 
irreversible lung disease but which is amenable to early intervention meaning there are significant 
potential benefits from early diagnosis. 
4. Genetics of PCD 
PCD is primarily an autosomal recessive disease. Unlike CF, PCD is a markedly genetically 
heterogeneous condition with mutations in the 27 known genes (Table 1) accounting for 50%–60% of 
PCD cases [12]. Whilst the CFTR gene associated with CF was identified in 1989 [35], it was not until 
2000 that the first gene associated with PCD was reported [9]. The gene was DNAH5 which is a cause 
of defects of the dynein arms. DNAI1 identification followed soon after [36]. DNAI1 or DNAH5 
mutations account for the majority of genetic mutations in North America [10,37]. Approximately  
50%–60% of PCD patients have bi-allelic mutations in a known PCD gene. Most of these mutations 
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correspond to a specific ultrastructural defect. For example, ZMYND10 [38] and DYX1C1 [39] are 
associated with inner and outer dynein arm defects whilst mutations in CCDC39 and CCDC40 lead to 
axonemal disorganisation and absent inner dynein arms [40]. DNAH11 was identified in 2002 in a 
patient with normal ciliary ultrastructure on EM [41] and accounts for 22% of those with normal 
ultrastructure [42]. Recently, mutations of the HYDIN gene were noted to be associated with 
apparently normal ultrastructure using conventional EM but by using a tomography approach an 
abnormality of the central pair apparatus was seen [20]. Many of the early identifications of genes used 
a candidate gene approach but recent discoveries such as HEATR2 and ARMC4 have been made 
through ciliome, exome or whole genome sequencing [43,44]. 
Table 1. Genes with mutations linked to primary ciliary dyskinesia. ODA—outer dynein 
arms, IDA—inner dynein arms. 
Gene Structural Defect 
Abnormalities in dynein proteins 
DNAI1 ODA defect (+/− IDA) 
DNAH5 ODA defect (+/− IDA) 
DNAH11 Beat abnormalities (normal structure) 
DNAI2 ODA defect 
DNALI1 ODA defect 
TXNDC3 ODA defect 
ARMC4 ODA defect 
Genes coding for proteins responsible for assembly or transport of axonemal proteins 
KTU ODA and IDA defects 
LRRC50 ODA and IDA defects 
DNAAF3 ODA and IDA defects 
CCDC39 ODA and IDA defects 
CCDC40 Axone disorganisation and IDA defect 
CCDC103 ODA and IDA defects 
CCDC114 ODA defect 
HEATR2 Absent ODA 
CCDC65 Cilial vibration, normal structure 
ZMYND10 Absent ODA + IDA 
SPAG1 Absent ODA + IDA 
C21orf59 Absent ODA + IDA 
Central pair abnormalities 
RSPH9 Central pair defects 
RSPH4A Central pair defects 
RSPH1 Central pair defects 
HYDIN Central pair defects 
Nexin-dynein complex defects 
DRC CCDC164 Nexin link missing 
CCDC65 Beat abnormalities 
Genes causing PCD with associated syndromes 
OFD1 Unknown 
RPGR Variable 
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The majority of PCD associated genes are rare and sometimes linked to only one or two affected 
families. Genetic diagnostics might therefore focus on a few of the more common mutations, much as 
CF screening programs concentrate on only a few of the almost 2000 known CFTR mutations [45]. 
Patients with identified mutations generally have biallelic mutations at a single locus, for example 
two mutated copies of DNAH5. Given the number of different possible mutations at each locus, the 
disease phenotype will often be the result of compound heterozygosity with the potential of mutations 
at different loci combining to cause a clinical phenotype. Indeed, single allele DNAH5 mutations are 
found in around 7% of PCD patients with no other mutation found [37]. Similarly, a patient with a 
single allele DNAH11 mutation has been reported with a classical PCD phenotype [46]. 
A challenge facing researchers seeking new mutations is the huge volume of genetic data generated 
by advances in sequencing and the need for sophisticated bioinformatics. Techniques such as whole 
exome sequencing produce a huge number of variations and require sophisticated algorithms to 
analyse and process these variations. International collaborations advancing our knowledge of disease 
associated variation ensure data can be appropriately analysed and verified [47]. 
5. Comparison of Primary Ciliary Dyskinesia and Cystic Fibrosis 
Although PCD and CF are both recessively inherited causes of chronic suppurative lung disease, 
there are a number of differences in both pathogenesis and aetiology. CF is associated with defects of a 
single gene, the cystic fibrosis transmembrane conductance regulator (CFTR) gene which encodes the 
chloride channel of the same name. To date, almost 2000 CFTR mutations have been identified [45]. 
Targeted mutation analysis with the American College of Medical Genetics 25 mutation panel detects 
at least one mutation in 88% of CF cases [48] whilst sequence analysis detects up to 98.7% of known 
CFTR mutations [49]. Neonatal CF screening is now in place in a number of countries worldwide 
including the U.S., UK and Australia, and many parts of Europe, Russia and Canada; though not all of 
these include DNA analysis within their newborn screening program. All screening protocols rely on 
the collection of blood spots in the newborn period for analysis of immunoreactive trypsin (IRT) 
levels. In the UK, those with IRT above the 99.5th centile are sent for analysis of the four commonest 
mutations with two mutations in a patient resulting in a label of “probably CF”. The presence of a 
single mutation leads to further 29–31 gene analysis whilst the presence of no mutations leads to 
further IRT analysis [50,51]. The U.S. approach varies across states whilst European practice varies 
widely, for example, Poland use an initial 640 mutation panel with complete sequencing of the CFTR 
gene if only one mutation is found [52]. Although very sensitive, this last approach can yield a high 
number of mutations of variable penetrance and expression. The potential benefits of NBS in PCD 
were demonstrated by a study of CF in London that NBS showed a reduction in the median age at 
diagnosis (excluding those with meconium ileus) from 2.4 years to 3 weeks [53]. 
PCD is currently associated with 27 different genes but with several hundred different proteins 
potentially affected, the task of identifying disease causing mutations is made all the more difficult. 
This difficulty is reflected in the fact that only 60% of North American PCD cases have an identified 
genetic mutation [54], the same proportion that are accounted for by a single mutation in CF (δF508 
homozygotes) [50]. Targeted mutation analysis has not been effective in PCD as each gene may have 
many different mutations associated with clinical disease, each of which is very rare; however next 
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generation sequencing panels have been developed that can screen known genes by comparing them to 
reference genomes. Next generation sequencing techniques, such as whole exome sequencing, may 
also expand the number of known disease associated loci [43]. 
Another major difference in CF is that the NBS has IRT as a reliable investigation to screen patients 
prior to genetic testing [55]. Effective PCD screening should also rely on a simple screening test with 
nasal nitric oxide (NO) a seemingly good candidate as it forms part of the European consensus 
guidelines [14]. However, specificity is unacceptably low in young children, precisely the group that 
screening needs to target. At the moment, we are therefore dependent on increased awareness of PCD by 
neonatologists and family doctors who should refer to specialist diagnostic centres when concerned [13]. 
As more genes are recognized and the cost of genetic testing comes down, it is likely that patients with 
even mild neonatal symptoms will be able to have DNA samples sent for screening with less need to 
travel to a specialist centre for brushing biopsy. 
Screening and genetic testing does not replace formal diagnostic studies; sweat testing still forms 
part of the CF diagnostic pathway and it is likely that functional ciliary assessment will continue to be 
required for a diagnosis of PCD to be made. However, CF patients have benefited from increasing 
genotype-phenotype correlation and, in the most striking example, genotype specific treatment with 
ivacaftor for G551D mutations [56]. Greater genotype-phenotype classification is an area where PCD 
patients may derive most benefit from genetic testing. 
6. Conclusions 
The combination of low incidence and relatively low sensitivity of genetic testing in PCD means 
that general population screening is not likely to be viable in the near future, however it may be 
appropriate in populations where PCD is common, for example the Asian population of Bradford [3]. 
The incidence of situs inversus in the general population is thought to be around 1 in 10,000 with many 
of these cases associated with PCD [11], therefore all cases with any respiratory symptoms should be 
referred for assessment and the availability of rapid genetic testing may aid diagnosis. It may also be 
possible to screen neonates with persistent tachypnoea and other features suggestive of PCD with rapid 
genetic sequencing; though it would be important to consider the sensitivity of genotyping so the 
correct children could also be assessed using HSV and EM assessments. 
PCD and CF are both autosomal recessive disorders causing chronic suppurative lung disease, 
raising the possibility of applying some of the CF genetic screening successes to PCD. The difficulties 
in achieving this reflect that CF is related to just one gene (CFTR) with mutation detection possible in 
up to 98.7% of cases whilst PCD involves 27 known and several hundred potential genes, a variety of 
mutations within each of these genes and, at present, the ability to detect a mutation in only 60% of 
cases. Additionally, in CF IRT provides a good newborn screening test, but in PCD low nNO, which is 
a good screening test in older children and adults, is not sufficiently specific in infancy. Genetic testing 
does not currently form part of the European diagnostic pathway in PCD [14], however, next 
generation sequencing techniques will both expand the known disease loci in PCD and improve the 
feasibility of rapid gene sequencing; thus increasing the role of genetic testing in PCD. Additionally, as 
genotype-phenotype correlation is improved, patients may benefit from more specific information on 
disease characteristics and, potentially, mutation specific treatments. The need for cilial structure and 
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beat analysis is only likely to be reduced once NO screening, genetic testing sensitivity and  
genotype-phenotype correlation are suitably robust. 
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